MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
DENTSPLY SIRONA EBITDA 2011-2026 | XRAY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA DENTSPLY SIRONA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -530 M | 258 M | -609 M | 955 M | 331 M | 676 M | 680 M | 830 M | 750 M | 563 M | 586 M | 560 M | 537 M | 422 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 955 M | -609 M | 429 M |
Quarterly EBITDA DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -126 M | -40 M | 142 M | - | -373 M | 136 M | 128 M | - | - | - | 29 M | - | -1.13 B | 178 M | 126 M | - | 226 M | 218 M | 182 M | - | 186 M | -39 M | -93 M | 137 M | 211 M | 138 M | 82.2 M | 81.8 M | 149 M | -1.09 B | 102 M | -706 M | 202 M | -986 M | 115 M | 134 M | 214 M | 176 M | 96.2 M | 93.1 M | 160 M | 125 M | 117 M | 103 M | 173 M | 169 M | 127 M | 97.4 M | 167 M | 165 M | 114 M | - | 148 M | 149 M | 107 M | - | 86.9 M | 129 M | 114 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | -1.13 B | 23.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 201.96 | -0.38 % | $ 58.1 B |  USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
Baxter International
BAX
|
1.01 B | $ 19.68 | -2.36 % | $ 10 B | USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
ICU Medical
ICUI
|
262 M | $ 148.29 | -1.92 % | $ 3.62 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 8.55 | -2.14 % | $ 177 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-8.85 M | $ 8.05 | -8.37 % | $ 162 M | USA |
 |
Repro Med Systems
KRMD
|
-9.4 M | $ 5.71 | -3.06 % | $ 260 M | USA |
 |
Alcon
ALC
|
580 M | $ 80.41 | -0.56 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
-164 M | $ 132.15 | -0.06 % | $ 7.04 B | USA |
 |
AtriCure
ATRC
|
-28.8 M | $ 37.74 | 0.27 % | $ 1.77 B | USA |
 |
Merit Medical Systems
MMSI
|
258 M | $ 82.7 | -0.66 % | $ 4.81 B | USA |
 |
electroCore
ECOR
|
-18.3 M | $ 6.37 | 0.63 % | $ 35.1 K | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 10.01 | -1.67 % | $ 409 M | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 82.71 | -0.62 % | $ 16.5 B | USA |
 |
LeMaitre Vascular
LMAT
|
61.9 M | $ 83.44 | -0.47 % | $ 1.87 B | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 77.39 | -6.65 % | $ 3.9 B | USA |
 |
Harvard Bioscience
HBIO
|
3.37 M | $ 0.59 | -4.27 % | $ 25 M | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 110.09 | -0.87 % | $ 5.33 B | USA |
 |
OraSure Technologies
OSUR
|
-17.4 M | $ 2.63 | -2.23 % | $ 196 M | USA |
 |
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
-94.8 M | $ 153.57 | -9.12 % | $ 4.79 B | USA |
 |
Intuitive Surgical
ISRG
|
2.79 B | $ 566.72 | -1.05 % | $ 201 B | USA |
 |
Microbot Medical
MBOT
|
-9.75 M | $ 2.11 | -1.17 % | $ 21.5 M |  Israel |
 |
STERIS plc
STE
|
1.34 B | $ 259.26 | -0.59 % | $ 25.6 B | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 4.58 | 0.82 % | $ 47.6 M | USA |
 |
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | 0.17 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-915 M | $ 23.06 | -1.37 % | $ 3.97 B | USA |
 |
Predictive Oncology
POAI
|
-10.8 M | $ 6.94 | 0.51 % | $ 37.8 M | USA |
 |
Utah Medical Products
UTMD
|
17.4 M | $ 59.88 | - | $ 217 M | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 40.48 | -6.45 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
-43 M | $ 14.13 | -3.02 % | $ 679 M | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 167.67 | -0.43 % | $ 9.34 M | USA |
 |
ResMed
RMD
|
1.16 B | $ 258.36 | 0.2 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 24.07 | 0.12 % | $ 1.11 B | USA |
 |
Stereotaxis
STXS
|
-21.2 M | $ 2.57 | -0.19 % | $ 207 M | USA |
 |
Retractable Technologies
RVP
|
-13.5 M | $ 0.75 | -1.32 % | $ 22.5 M | USA |
 |
STAAR Surgical Company
STAA
|
-5.72 M | $ 21.42 | -2.7 % | $ 1.05 B | USA |
 |
Teleflex Incorporated
TFX
|
426 M | $ 106.84 | -1.58 % | $ 5 B | USA |
 |
West Pharmaceutical Services
WST
|
725 M | $ 273.48 | 0.26 % | $ 20 B | USA |